Cipla Receives FDA Approval for Generic Nintedanib Capsules to Treat Idiopathic Pulmonary Fibrosis
核心洞察
Cipla USA Inc (搜索). received final FDA approval for its generic nintedanib capsules (100mg and 150mg) as a therapeutic equivalent to Boehringer Ingelheim's Ofev® for treating idiopathic pulmonary fibrosis (搜索).
The approval strengthens Cipla's respiratory franchise and provides patients with access to high-quality treatment options for IPF (搜索), a chronic progressive lung disease characterized by irreversible lung tissue scarring.
The generic launch targets a significant market opportunity, as Ofev® generated approximately $3.76 billion in U.S. sales according to IQVIA data from January 2026.
Cipla USA Inc (搜索)., the wholly owned subsidiary of Cipla Limited, announced it has received final approval from the U.S. Food and Drug Administration (搜索) for its Abbreviated New Drug Application for Nintedanib Capsules in 100 mg and 150 mg strengths, indicated for the treatment of Idiopathic Pulmonary Fibrosis (搜索) (IPF (搜索)). The company is set to launch the generic medication on an immediate basis.
Generic Alternative to Major IPF Treatment
Cipla's nintedanib capsules serve as the generic therapeutic equivalent of Ofev®, which is marketed by Boehringer Ingelheim. IPF (搜索) is a chronic, progressive lung disease characterized by irreversible scarring of lung tissue, leading to declining lung function and significant impact on patients' quality of life.
The approval represents entry into a substantial market, with Ofev® generating approximately $3.76 billion in U.S. sales according to IQVIA MAT January 2026 data, underscoring the importance of reliable, high-quality treatment options in this therapeutic category.
Strategic Expansion of Respiratory Portfolio
Marc Falkin, CEO of Cipla North America, commented on the approval: "This approval strengthens our respiratory franchise and reflects our continued commitment to delivering high-quality therapies to patients. We are well prepared with a robust supply plan to support a successful launch."
The product will be available through appropriate pharmacy distribution channels, including specialty distribution networks, ensuring broad accessibility for patients requiring IPF (搜索) treatment.
Company Background and Market Position
Established in 1935, Cipla is a global pharmaceutical company focused on agile and sustainable growth, complex generics, and deepening portfolio in home markets including India, South Africa, North America, and key regulated and emerging markets. The company's strengths span respiratory, antiretroviral, urology, cardiology, anti-infective and CNS segments.
Cipla operates 46 manufacturing sites worldwide, producing over 50 dosage forms and 1,500+ products using cutting-edge technology platforms to serve more than 80 markets. The company holds significant market positions, ranking as the 3rd largest pharma company in India according to IQVIA MAT December 2025, 2nd largest in the pharma prescription market in South Africa per IQVIA MAT November 2025, and 3rd largest by prescription in the US generics respiratory products according to IQVIA MAT December 2025.